BillionToOne, Inc. (BLLN)
Health Care · Molecular Diagnostics / Liquid Biopsy · Nasdaq
BillionToOne uses breakthrough single-molecule sequencing technology to detect sparse disease signals in blood with unprecedented precision for prenatal and cancer diagnostics.
What BillionToOne, Inc. does
BillionToOne develops molecular diagnostic tests using its proprietary single-molecule next-generation sequencing (smNGS) platform with Quantitative Counting Templates (QCTs) to detect genetic targets with single-molecule sensitivity. The company offers UNITY, a non-invasive prenatal test (NIPT) for fetal risk assessment of recessive conditions, and Northstar Select and Northstar Response, pan-cancer liquid biopsy tests for therapy selection and treatment response monitoring. Its AI-enhanced workflow and smNGS technology enable detection of sparse disease signals in cell-free DNA with greater precision than conventional NGS methods.
Themes: ["Prenatal diagnostics / recessive condition screening","Non-invasive prenatal testing (NIPT)","Liquid biopsy / circulating tumor DNA","Pan-cancer oncology diagnostics","Treatment response monitoring","Precision diagnostics / personalized medicine","Molecular sequencing technology"]
Fundamentals
- Price$126.77 as of 2026-07-10 close
- Market cap$5.8B as of 2026-07-12
- 1-year return+54.9% as of 2026-07-10 close
- P/E229.34 as of 2026-07-12
- Net margin+6.2% as of 2026-07-12
- Gross margin+69.5% as of 2026-07-12
- ROE+7.6% as of 2026-07-12
- Debt / equity0.20 as of 2026-07-12
- Revenue growth (YoY)-37.0% as of 2026-07-12
- Revenue CAGR (3y)+106.2% SEC XBRL
- Beta1.01 as of 2026-07-12
Key risks (from latest filing)
["Revenue decline of 37% YoY signals execution challenges or market adoption headwinds in core products, despite profitable status","Competitive pressure from established diagnostics companies launching competing NIPTs and liquid biopsies; UNITY Fetal Antigen CTA and Northstar expansion dependent on clinical validation and reimbursement strategy execution","Material weaknesses in internal control over financial reporting acknowledged in filings; regulatory and reimbursement pathway uncertainty for novel companion diagnostics and methylation-based assays"]
Competitors & peers
- Illumina (ILMN)
- Natera (NTRA)
- Invitae (NVTA)
- GRAIL (acquired by Illumina)
- Foundation Medicine (FMI, acquired by Roche)
- Guardant Health (GH)
- Personalis (PSNL)
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.